Unsurprisingly, S1P3 has been validated as a therapeutic target for drug development to treat cerebral ischemia because CAY10444 administration can attenuate brain damages such as brain infarction, neurological functional deficit, and neural cell death after tMCAO challenge [94]. This evidence concerns the gene S1PR3 and brain ischemia.